Reuters

Insight: Chasing cheaper cancer drugs

Share Slideshow

A girl suffering from cancer rests inside the children's ward at the Cancer Centre Welfare Home and Research Institute in Kolkata March 16, 2012. India, a country with a long history of making cheap off-patent drugs and a sometimes brittle relationship with Western drugmakers, has finally lost patience. New Delhi shocked the global drugs industry in March by effectively ending Bayer's monopoly on kidney and liver cancer drug...more

A girl suffering from cancer rests inside the children's ward at the Cancer Centre Welfare Home and Research Institute in Kolkata March 16, 2012. India, a country with a long history of making cheap off-patent drugs and a sometimes brittle relationship with Western drugmakers, has finally lost patience. New Delhi shocked the global drugs industry in March by effectively ending Bayer's monopoly on kidney and liver cancer drug Nexavar and issuing its first-ever compulsory licence, allowing local generic firm Natco Pharma to produce and sell the drug cheaply in India. In a move to head off the same threat to its patented drugs, Roche, the world's biggest maker of cancer medicines, plans to offer significantly cheaper locally branded versions of two other cancer treatments, Herceptin and MabThera, under an alliance with Emcure Pharmaceuticals. Picture taken March 16, 2012. REUTERS/Rupak De Chowdhuri/Files
Close
1 / 2

A woman with cancer sits on a pavement outside the Tata Memorial Hospital in Mumbai March 15, 2012. India, a country with a long history of making cheap off-patent drugs and a sometimes brittle relationship with Western drugmakers, has finally lost patience. New Delhi shocked the global drugs industry in March by effectively ending Bayer's monopoly on kidney and liver cancer drug Nexavar and issuing its first-ever compulsory...more

A woman with cancer sits on a pavement outside the Tata Memorial Hospital in Mumbai March 15, 2012. India, a country with a long history of making cheap off-patent drugs and a sometimes brittle relationship with Western drugmakers, has finally lost patience. New Delhi shocked the global drugs industry in March by effectively ending Bayer's monopoly on kidney and liver cancer drug Nexavar and issuing its first-ever compulsory licence, allowing local generic firm Natco Pharma to produce and sell the drug cheaply in India.In a move to head off the same threat to its patented drugs, Roche, the world's biggest maker of cancer medicines, plans to offer significantly cheaper locally branded versions of two other cancer treatments, Herceptin and MabThera, under an alliance with Emcure Pharmaceuticals. Picture taken March 15, 2012. REUTERS/Vivek Prakash/Files
Close
2 / 2

All Collections

Pictures of the year: Sports

Thursday, December 18, 2014

All Collections

In the heart of Ebola

Thursday, December 18, 2014

All Collections

Inside the Peshawar school

Thursday, December 18, 2014

All Collections

Pictures of the year: Rise of ISIS

Thursday, December 18, 2014

All Collections

Protecting the President

Thursday, December 18, 2014

All Collections

Inside North Korea

Thursday, December 18, 2014

All Collections

Behind the wheel in Kabul

Thursday, December 18, 2014

All Collections

U.S. and Cuba restore ties

Thursday, December 18, 2014